First AD

Second AD

Less Common Molecular Alterations in pLGG and Testing Recommendations

Are there particular considerations depending on the type of BRAF alteration?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG)

The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for patient care.

Overview of pLGG presentation and categorization

Molecular Characterization of pLGG

Standard of care for frontline treatment of non-V600E-specific pLGG tumors

Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

Current Treatment of Patients with NF1 pLGG

Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

Treatment Considerations for Progressive pLGG

Radiation and Targeted Therapies for Progressive pLGG

The Role of Tovorafenib in Treatment of Progressive pLGG

Clinical Trials to Increase Treatment Options in the Progressive Setting

Clinical scenario 1 - BRAFKIAA-1549 fusion

Alternatives and Considerations for Clinical Scenario 1

Clinical Scenario 2 - BRAFV600E

Potential Adverse Events With Targeted Therapies

Clinical Insights: Looking Forward for pLGG